Funding rounds, M&A, IPOs, and market analysis—where capital is flowing and why the tape moves.
AusperBio has added $120 million in series C financing to advance its chronic hepatitis B oligonucleotide program, led by late-stage candidate AHB-137. The round gives the Bay Area biotech fresh capital to fund phase 3 work in China and extend its platform beyond a single asset.
AusperBio has added $120 million in series C financing to advance its chronic hepatitis B oligonucleotide program, led by late-stage candidate AHB-137. The round gives the Bay Area biotech fresh capital to fund phase 3 work in China and extend its platform beyond a single asset.
READ MORE
Genentech agreed to pay DualityBio $45 million upfront in a deal worth more than $1 billion in potential milestones for ADC programs aimed at tumors that progress after existing topoisomerase-based drugs. The pact points to a new investment theme inside the crowded ADC field: designing for the resistance setting rather than only chasing new targets.
JATT III Acquisition has launched on Nasdaq with a $60 million IPO to pursue a reverse merger with a biotech or related life sciences company. The offering revives a structure that fell out of favor after its 2022 peak, even as more biotechs return to traditional IPOs.
Biohaven is handing SK Biopharmaceutical an exclusive global license to its Kv7 ion channel platform and lead epilepsy asset opakalim in a deal worth up to $795 million. The transaction brings substantial near-term cash while shifting milestone obligations tied to the platform.
Biotech IPO activity has climbed to 25 offerings so far this year, the highest pace since 2021. Leerink says the market is approaching “escape velocity,” but only if investors keep backing later-stage names with disciplined pricing.
Haisco Pharmaceutical Group has formed Sentivera with backing from Population Health Partners and ARCH Venture Partners in a deal potentially worth about $1.5 billion. The structure gives the new company rights outside China while Haisco keeps developing the asset in China.
Sword Health plans to acquire Headspace, according to a Massachusetts regulatory filing. The proposed cash deal would add a mental health company to Sword’s broader platform expansion.
TME Pharma said talks to license brain cancer drug NOX-A12 have narrowed to two potential partners. The outcome matters because the company says it needs a partner to move the asset into phase 2 development despite limited cash.
Abcuro has added $66 million in Series D financing to fund another clinical trial of ulviprubart in inclusion body myositis, focusing on patients with less severe disease after a prior Phase 2/3 result fell short of statistical significance. The financing gives the company a second attempt in a rare disorder with no FDA-approved therapies.
Kaos Capital is pressing Capricor Therapeutics for board changes and a capital-preservation plan as the company weighs an amendment to its deramiocel application that could extend its Aug. 22 action date. The dispute shifts attention from a single regulatory decision to how a small biotech manages concentration risk when most of its value rests on one asset.
Ambros Therapeutics plans to become a public company through an all-stock merger with Werewolf Therapeutics, backed by a $150 million private placement expected to fund its CRPS-1 program through regulatory submission. The deal channels public-market capital into a late-stage rare pain asset in an area with no FDA-approved therapies.
